Marion McCourt

Executive Vice President, Commercial · Regeneron Pharmaceuticals

Biopharmaceuticals

Marion McCourt is executive vice president and head of the commercial organization at Regeneron Pharmaceuticals. She joined in February 2018 after operational and commercial leadership at Axovant, Medivation, Amgen and AstraZeneca.

Last reviewed: Oct 21, 2026

Marion McCourt

Executive Vice President, Commercial Regeneron Pharmaceuticals

Last Reviewed: October 21, 2026

Executive Summary

Marion McCourt is executive vice president and head of the commercial organization at Regeneron Pharmaceuticals. She joined in February 2018 after operational and commercial leadership at Axovant, Medivation, Amgen and AstraZeneca.

Career Highlights

  • Joined Regeneron in February 2018 and became executive vice president in January 2021.
  • Previously served as president and chief operating officer at Axovant.
  • Earlier held COO positions at Medivation and AstraZeneca U.S.

Professional Journey

McCourt developed her pharmaceutical career at AstraZeneca over twelve years. She served as president and CEO of AstraZeneca Canada in 2011–2012 and chief operating officer of AstraZeneca U.S. in 2012–2013.

She moved to Amgen in 2013 as vice president and general manager of its Bone Health and Primary Care business unit. From February 2014 through January 2016, she was a vice president in U.S. Commercial Operations. She then served as chief operating officer at Medivation until its acquisition by Pfizer in 2016.

In April 2017, McCourt became president and chief operating officer of Axovant. She joined Regeneron in February 2018 as senior vice president and head of Commercial, becoming executive vice president in January 2021. Her progression connects country management and operating leadership with oversight of the commercial organization at a research-driven biotechnology company.

Education

McCourt earned a BS in biology from Lafayette College.